The Rosen Law Firm, P.A. announces that it has commenced an investigation into allegations that Prosensa Holding NV (NASDAQ:RNA) may have violated federal securities laws by issuing false and misleading statements to investors about its business and financial condition. Prosensa Holding NV is a biotechnology company that develops ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The Company focuses on neuromuscular and neurodegenerative disorders, including Duchenne muscular dystrophy (“DMD”), myotonic dystrophy and Huntington's disease. The Company’s lead product candidate is drisapersen, which aims to treat DMD. The investigation relates to allegations that the Company’s Registration Statement and Prospectus issued in connection with its initial public offering on June 28, 2013 were materially false and misleading. Specifically, the investigation focuses on allegations that the Prosensa misrepresented or failed to disclose material facts concerning the efficacy of drisapersen and its prospects for marketing and regulatory approval. The Rosen Law Firm is preparing a securities class action lawsuit on behalf of Prosensa investors. If you purchased Prosensa stock please visit the website at http:/rosenlegal.com to join the class action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.